Trevena Inc (TRVN) - Total Assets
Based on the latest financial reports, Trevena Inc (TRVN) holds total assets worth $19.19 Million USD as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Trevena Inc to assess how comfortably operating cash covers total debt obligations.
Trevena Inc - Total Assets Trend (2011–2023)
This chart illustrates how Trevena Inc's total assets have evolved over time, based on quarterly financial data. See what is Trevena Inc's book value for net asset value and shareholders' equity analysis.
Trevena Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Trevena Inc's total assets of $19.19 Million consist of 86.7% current assets and 13.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 81.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2023)
This chart illustrates how Trevena Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Trevena Inc (TRVN) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Trevena Inc's current assets represent 86.7% of total assets in 2023, a decrease from 89.8% in 2011.
- Cash Position: Cash and equivalents constituted 81.2% of total assets in 2023, down from 87.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Trevena Inc Competitors by Total Assets
Key competitors of Trevena Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Trevena Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.42 | 6.41 | 4.12 |
| Quick Ratio | 2.42 | 6.27 | 4.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.65 Million | $33.32 Million | $28.38 Million |
Trevena Inc - Advanced Valuation Insights
This section examines the relationship between Trevena Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.36 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -16.6% |
| Total Assets | $40.60 Million |
| Market Capitalization | $9.50K USD |
Valuation Analysis
Below Book Valuation: The market values Trevena Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Trevena Inc's assets decreased by 16.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Trevena Inc (2011–2023)
The table below shows the annual total assets of Trevena Inc from 2011 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $40.60 Million | -16.59% |
| 2022-12-31 | $48.68 Million | -39.24% |
| 2021-12-31 | $80.12 Million | -37.28% |
| 2020-12-31 | $127.74 Million | +171.82% |
| 2019-12-31 | $46.99 Million | -29.63% |
| 2018-12-31 | $66.78 Million | -8.17% |
| 2017-12-31 | $72.72 Million | -36.57% |
| 2016-12-31 | $114.65 Million | -34.62% |
| 2015-12-31 | $175.35 Million | +61.86% |
| 2014-12-31 | $108.34 Million | +155.56% |
| 2013-12-31 | $42.39 Million | +424.17% |
| 2012-12-31 | $8.09 Million | -58.33% |
| 2011-12-31 | $19.41 Million | -- |
About Trevena Inc
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the… Read more